Tagworks Pharmaceuticals, based at Radboud University Medical Center, have developed a novel technique for the targeted delivery of ADCs to treat tumors. By the controlled 'click-to-release' of the chemotherapy drug from its tumor-binding carrier, the treatment would reach the right location.
A new clinical trial executed under lead investigator, Professor Chris Hollis from the University of Nottingham in the UK, revealed that by adding a computerized test of attention and activity (QbTest) to standard subjective assessments, the clinicians could easily make a diagnostic decision on ADHD, with proper accuracy.
A research team at Tufts University revealed that good microbes in gastrointestinal tract could prevent liver inflammation, the major symptom of NAFLD. When the research was conducted on a mice model, they identified two key metabolites produced by the bacteria namely I3A and TA, which could ultimately reduce the severity of NAFLD.
In 2017, the movable imaging systems segment generated revenue of US$8,384.9 million and held a solid position in the operating room equipment segment.
The company informed that Ryaltris (olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg), formerly GSP 301 Nasal Spray, has been conditionally accepted by the USFDA as the brand name.
A research team led by Dr. Beatrice Nardone, research assistant professor of dermatology at Northwestern University Feinberg School of Medicine, discovered that daily consumption of aspirin could significantly increase the risk for melanoma (skin cancer) in men, compared to women.
At present, hearing loss could be diagnosed only by hearing tests such as audiogram. But it was impossible to detect at an earlier stage itself. Similarly, it was equally challenging to detect vertigo where several expensive and time-consuming imaging tests are used.
As ImmusanT initiates the process to develop its treatment regimens for celiac disease and Type 1 diabetes, the company has fast-paced its hiring activity by bringing on board Ken Truitt M.D. Daiichi Sankyo’s SVP for internal medicine therapeutics as its new Chief Medical Officer.
Recently in an annual meeting of ARVO (Association for Research in Vision and Ophthalmology) which had taken place in Hawaii, Sylentis – the pharma company belonging to PharmaMar Group and a pioneer in RNAi research, had presented the positive results from the clinical studies on tivanisiran therapy against dry eye syndrome.
The annual meeting of the American Urological Association had Sesen Bio present its three-month data for its bladder cancer treatment Vicinium. This was Sesen Bio’s first readout following its name change from Eleven Biotherapeutics.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.